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1Von Willebrand factor (VWF) is a multimeric protein that is secreted via Weibel–Palade bodies in endothelial 
cells and α-granules in platelets into flowing blood. Secreted 
ultralarge VWF multimers can remain transiently bound to 
the endothelial cell surface or be released into the circula-
tion. Unfolding of VWF by shear stress induces a conforma-
tional change, making the A2 domain available for proteolytic 
cleavage by ADAMTS13 (a disintegrin and metalloprotein-
ase with a thrombospondin type 1 motif, member 13). This 
proteolysis decreases the size of VWF, thereby reducing its 
thrombotic potential.1 A deficiency in ADAMTS13 activity is 
associated with thrombotic thrombocytopenic purpura (TTP), 
a life-threatening disease characterized by thrombocytopenia 
and hemolytic anemia.2 These conditions are a result of the 
formation of microthrombi in the smaller capillaries and lead 
to fever, neurological complications, renal impairment, and 
death through organ failure when left untreated.3
Decreased enzymatic activity may be caused by muta-
tions in the ADAMTS13 gene and result in congenital TTP.1,4 
However, the vast majority of patients have acquired TTP, 
where anti-ADAMTS13 autoantibodies either neutralize 
the activity of ADAMTS13 or enhance protein clearance.5,6 
Standard of care treatment of acquired TTP patients con-
sists of frequent plasma exchange with fresh frozen plasma 
and additional immunosuppressive treatment with cortico-
steroids or other agents, such as rituximab or cyclosporine.7,8 
Plasma exchange is performed to remove inhibitory antibod-
ies from the circulation and replenish ADAMTS13 enzyme 
activity. However, not all patients respond to this treatment 
method, and only 80% to 90% survive an acute episode.9 In 
addition, plasma exchange is time consuming and requires 
large amounts of plasma. Therefore, new therapies are highly 
warranted.10
Replenishment of plasma ADAMTS13 activity with 
recombinant ADAMTS13 (rADAMTS13) could significantly 
improve TTP therapy and reduce the mortality rate. rAD-
AMTS13 therapy was in fact shown to result in decreased 
incidence and severity of TTP symptoms in a mouse model 
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of congenital TTP, where ultralarge VWF multimers serve 
as trigger for inducing TTP-like symptoms.11 However, the 
expected efficacy of rADAMTS13 replacement therapy for 
acquired TTP is likely complicated by the presence of free 
circulating anti-ADAMTS13 autoantibodies that bind and 
neutralize infused rADAMTS13. Nevertheless, because the 
addition of increasing concentrations of rADAMTS13 to 
plasma of acquired TTP patients normalized ADAMTS13 
activity in vitro by overriding the inhibitory antibodies,12 
rADAMTS13 therapy seems to be a promising treatment 
opportunity for this patient group. In the presented study, we 
developed a rat model mimicking various aspects of acquired 
TTP, with which we further explored the feasibility of rAD-
AMTS13 treatment in acquired TTP.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Establishing a Rat Model Resembling Acquired TTP
First, rats were injected with polyclonal anti-ADAMTS13 
antibodies (650 U/kg) to block endogenous rat ADAMTS13 
activity and to establish a robust inhibitor titer of ≈10 BU/
mL. Then, animals were administered 2000 U/kg recombi-
nant VWF (rVWF) to trigger TTP symptoms.11 Control ani-
mals received either control IgG instead of anti-ADAMTS13 
antibodies or saline instead of rVWF. Animals were followed 
for 24 h, and blood samples were analyzed after 3 and 24 
h. The normal platelet count at baseline was 650±177×103 
platelets/μL blood (Figure 1A). Rats injected with anti-
ADAMTS13 antibodies and triggered with rVWF developed 
thrombocytopenia, with a platelet count of 427±111×103/μL 
after 3 h and 218±40×103/μL after 24 h (Figure 1A). Neither 
injection of anti-ADAMTS13 antibodies without additional 
rVWF nor injection of control IgG with rVWF resulted in 
thrombocytopenia (652±146×103/μL and 766±63×103/μL 
after 24 h, respectively; Figure 1A). Hemoglobin levels also 
decreased significantly after 24 h when rats developed TTP 
(from 14.7±1.0 g/dL at baseline to 11.7±1.1 g/dL at 24 h ver-
sus 13.6±0.9 g/dL for anti-ADAMTS13+saline and 14.2±0.5 
g/dL for control IgG+rVWF) as depicted in Figure 1B.
To further confirm the TTP phenotype, lactate dehydro-
genase (LDH) activity, a marker for tissue damage, was mea-
sured in rats. In animals with TTP, a highly increased LDH 
activity was observed 3 h after disease induction (1289.5±63.3 
mU/mL; Figure 1C). After 24 h, the LDH activity returned to 
normal levels (69.0±75.2 mU/mL; Figure 1C). Additionally, 
the percentage of schistocytes present in the blood was quan-
tified, but no significant difference was observed between the 
groups. Next, rat brain and kidney sections were analyzed for 
the presence of microthrombi. In animals injected with anti-
ADAMTS13 antibodies and triggered with saline, no micro-
thrombi were observed (Figure 1D, left). However, rats having 
acquired TTP-like symptoms as a result of injection of anti-
ADAMTS13 antibodies and rVWF showed microthrombi in 
the brain, as well as increased VWF staining in the capillaries 
around the glomeruli in kidney sections (Figure 1D, right). 
The combined results demonstrate that the chosen setup 
induces severe TTP symptoms in rats, comprising thrombo-
cytopenia, hemolytic anemia, increased LDH activity, and the 
presence of VWF-rich microthrombi, and can thus be regarded 
as a valid animal model for key aspects of acute acquired TTP.
rADAMTS13 Prevents Thrombocytopenia 
and Hemolytic Anemia
To evaluate the potential efficacy of rADAMTS13 for acquired 
TTP in our rat model, TTP symptoms were triggered with anti-
ADAMTS13 antibodies and rVWF. Fifteen minutes thereaf-
ter, animals were injected with vehicle or rADAMTS13 (400, 
800, or 1600 U/kg). At this time point, the platelet count 
was already declined by 50%. Groups (n=6) were compared 
regarding the extent of TTP symptoms, including platelet 
counts, hemoglobin levels, and LDH activity after 3, 6, and 
24 h. In the 800 U/kg dose group, 2 rats were excluded from 
analysis: one because of an imperfect rVWF injection and one 
because of death for unknown reasons during anesthesia at 3 h.
As expected from our previous results, thrombocyto-
penia was observed in animals treated with vehicle alone 
(0 U/kg rADAMTS13, Figure 2A), with a platelet count of 
355±106×103/μL after 3 h, 231±102×103/μL after 6 h, and 
299±107×103/μL after 24 h (Figure 2A). After treatment with 
400, 800, or 1600 U/kg rADAMTS13, no thrombocytopenia 
was observed after 3, 6, and 24 h, demonstrated by compara-
ble platelet counts to those measured at baseline (751±93×103 
platelets/μL blood, Figure 2A). Hemoglobin levels also sig-
nificantly decreased in rats treated with vehicle after 24 h 
as depicted in Figure 2B (from 13.1±1.2 g/dL at baseline to 
10.9±1.3 g/dL at 24 h; Figure 2B). On treatment with rAD-
AMTS13, hemoglobin concentration values remained stable 
over time (Figure 2B). LDH activity increased in rats treated 
with vehicle 3 and 6 h after TTP induction (1020±352 and 
874±548 mU/mL; Figure 2C), with normal levels after 24 h 
(44.9±63.3 mU/mL). Injection of rADAMTS13 protected rats 
from cell and tissue damage because no increase in LDH activ-
ity was detected (Figure 2C). These data indicate that treatment 
with rADAMTS13 is able to prevent the development of severe 
TTP symptoms in our rat model mimicking acquired TTP.
rADAMTS13 Overrides Inhibitory Antibodies 
and Restores ADAMTS13 Activity
The amount of rADAMTS13 administered in our rat model 
appeared sufficient to complex all polyclonal anti-ADAMTS13 
antibodies present in plasma samples and to provide enough 
Nonstandard Abbreviations and Acronyms
ADAMTS13 a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif, member 13
HMW high molecular weight
LDH lactate dehydrogenase
rADAMTS13 recombinant ADAMTS13
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TTP thrombotic thrombocytopenic purpura
VWF von Willebrand factor
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free rADAMTS13 to digest UL-VWF. Immune complexes 
did in fact form between the polyclonal anti-ADAMTS13 
antibodies and endogenous ADAMTS13 and rADAMTS13 in 
plasma from rats treated with 400, 800, or 1600 U/kg rAD-
AMTS13 at 3 and 6 h after injection (significant for 1600 
U/kg compared with other doses), but not in animals that 
received vehicle (0 U/kg rADAMTS13; Figure 3A). After 24 
h, significant amounts of immune complexes were measured 
only in rats that received 1600 U/kg rADAMTS13.
Despite the formation of immune complexes, sufficient 
levels of free rADAMTS13 were present in the circulation 
after injection of 400, 800, or 1600 U/kg rADAMTS13. 
ADAMTS13 activity of 68.4%±21.9%, 101.2%±22.7%, and 
714.1%±817.9%, respectively, was detected in rat plasma after 
24 h (Figure 3B). Plasma from animals that received vehicle 
(0 U/kg rADAMTS13) showed no ADAMTS13 activity at 3 
and 6 h, but partly regained activity after 24 h (43.9%±33.5%; 
Figure 3B). In conclusion, despite the formation of immune 
Figure 1. Recombinant von Willebrand factor (rVWF) is able to trigger thrombotic thrombocytopenic purpura (TTP) symptoms in rats with 
anti-ADAMTS13 antibodies. Animals were administered 650 U/kg polyclonal anti-ADAMTS13 or IgG control antibodies (at 0 minutes) and 
2000 U/kg rVWF or saline (at 15 minutes). A and B, Platelet count and hemoglobin levels were measured in EDTA anticoagulated blood at 
baseline and 3 and 24 h after injections. C, Tissue damage was determined by measuring lactate dehydrogenase (LDH) activity in EDTA 
plasma. Graphs show mean±SD. *P<0.05; **P<0.01. Control IgG+rVWF, n=4; anti-ADAMTS13+saline, n=9; and anti-ADAMTS13+rVWF, 
n=7. D, After 24 h, animals were euthanized and tissues were removed for histological analysis. Sections were stained for VWF (brown 
staining). Top, Brain sections from control animals (left) and animals with acquired TTP (right). Scale bars indicate 20 μm. Bottom, Kid-
ney sections from control animals (left) and animals with acquired TTP (right). Scale bars indicate 50 μm. ADAMTS13 indicates a disinte-
grin and metalloproteinase with a thrombospondin type 1 motif, member 13.
Figure 2. Recombinant ADAMTS13 (rADAMTS13) treatment prevents severe thrombotic thrombocytopenic purpura (TTP) symptoms in 
rats with acquired TTP. Animals with acquired TTP were administered 0, 400, 800, or 1600 U/kg rADAMTS13 at 30 minutes. A and B, 
Platelet count and hemoglobin levels were measured in EDTA anticoagulated blood at baseline and 3, 6, and 24 h after injections. C, Tis-
sue damage was determined by measuring lactate dehydrogenase (LDH) activity in EDTA plasma. 0, 400, and 1600 U/kg, n=6; 800 U/kg, 
n=4. Graphs demonstrate mean±SD. *P<0.05; **P<0.01. ADAMTS13 indicates a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif, member 13.
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complexes, sufficient free rADAMTS13 was present in the 
circulation of all acquired TTP rats treated with the enzyme.
rADAMTS13 Treatment Reduces High 
Molecular Weight VWF Multimer Size
As expected, levels of rVWF, measured using an antigen 
ELISA specific for human VWF, were high in rat plasma 
samples 3 h after rVWF injection and gradually decreased 
after 6 and 24 h, reflecting the clearance of the protein over 
time (Figure 4A). Similar VWF levels were detected at all 3 
time points irrespective of rADAMTS13 dose, indicating that 
increased VWF proteolysis by rADAMTS13 did not influence 
VWF clearance, in line with previous observations.13
To confirm that successful treatment of acquired TTP-like 
symptoms in rats with rADAMTS13 was linked to proteolytic 
degradation of rVWF, the VWF multimer pattern was ana-
lyzed in plasma from all treated rats. To allow detection of 
rVWF but not endogenous rat VWF, a plasma volume was 
loaded at which a multimer pattern was only discernible for 
samples from rats treated with rVWF (Figure 4B). At this 
plasma dilution, rVWF multimers were observed after 3 and 
6 h, but at an intensity that fell below the detection limit at 24 
h. Using densitometry, the multimer pattern was analyzed, and 
the percentage of high molecular weight (HMW) multimers 
was calculated (Figure 4C).
Before injection, rVWF contained 47.9%±2.7% HMW 
multimers. After injection of 0 U/kg rADAMTS13 into rats, 
this value decreased to 36.4%±2.9% at 3 h and 30.3%±1.1% 
at 6 h. Administration of 400 U/kg rADAMTS13 did not alter 
the percentage of HMW multimers. A significantly lower per-
centage of HMW VWF multimers, however, was observed in 
rats that received 800 (32.2%±2.5% and 26.8%±1.6%) and 
1600 (28.8%±4.9% and 24.2%±5.5%) U/kg rADAMTS13. 
Thus, increasing concentrations of rADAMTS13 resulted in 
cleavage of HMW multimers into smaller, less-thrombogenic 
multimers.
rADAMTS13 Treatment Diminishes the 
Presence of VWF-Rich Microthrombi
Brain, kidney, liver, and lung sections were analyzed for the 
presence of microthrombi in untreated and treated rats. VWF-
specific brown staining was observed for all tissues in endothe-
lial cells lining the arteries. No microthrombi were observed 
in liver and lung sections. VWF-rich microthrombi were 
observed in brain sections of rats that received 0 U/kg rAD-
AMTS13 (Figure 5A, left), but not in those administered 400, 
Figure 3. Recombinant ADAMTS13 (rADAMTS13) overrides inhibitory antibodies and restores ADAMTS13 activity. A, Anti-ADAMTS13 
antibodies bound to endogenous or recombinant ADAMTS13 were measured as circulating immune complexes in citrated plasma using 
ELISA. B, ADAMTS13 activity was measured using FRETS-VWF73. Citrated plasma obtained at baseline and 3, 6, and 24 h after injec-
tions was used undiluted (0, 400, and 800 U/kg groups) or diluted in heat-inactivated rat plasma (1600 U/kg group). 100% activity cor-
responded with ADAMTS13 activity in normal rat plasma. 0, 400, and 1600 U/kg, n=6; 800 U/kg, n=4. Graphs demonstrate mean±SD. 
*P<0.05; **P<0.01. ADAMTS13 indicates a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; and VWF, 
von Willebrand factor.
Figure 4. Recombinant ADAMTS13 (rADAMTS13) 
treatment reduces high molecular weight (HMW) 
von Willebrand factor (VWF) multimer size. 
A, Human VWF antigen levels were determined in 
citrated plasma at baseline and 3, 6, and 24 h after 
injections using ELISA. B, VWF multimer analy-
sis was performed on citrated plasma samples 
obtained from rats 6 h after injection of 0 or 1600 
U/kg rADAMTS13. VWF was separated on SDS-
agarose gels, resulting in separation of the differ-
ent sized multimers. C, Densitometry analysis was 
performed on the VWF multimer gels. The total 
number of distinguishable bands was counted, and 
the relative abundance HMW multimers (>10-mer) 
was calculated relative to the complete multimer. 
0, 400, and 1600 U/kg, n=6; 800 U/kg, n=4. Graphs 
show mean±SD. *P<0.05; **P<0.01. ADAMTS13 
indicates a disintegrin and metalloproteinase with 
a thrombospondin type 1 motif, member 13; and 
rVWF, recombinant von Willebrand factor.
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800, or 1600 U/kg rADAMTS13 (Figure 5B). Microthrombi 
present in rats treated with vehicle were negative for fibrin 
(Figure 5A, right). In kidney sections, increased VWF stain-
ing but no fibrin staining was observed in the capillaries 
around the glomeruli of rats that did not receive rADAMTS13 
compared with rADAMTS13-treated rats (Figure 5C). These 
results demonstrate that rats with acquired TTP-like symp-
toms formed VWF-rich, fibrin-poor microthrombi in the brain 
and kidney and that treatment with rADAMTS13 reduced this 
microthrombi formation and, thus, also TTP symptoms.
Discussion
We have developed a rat model resembling acquired TTP, in 
which rADAMTS13 was demonstrated to avert several severe 
symptoms typical of this disease, including thrombocytope-
nia, hemolytic anemia, increased LDH activity, and VWF-rich 
microthrombi in the small arterioles.
Several novel therapeutic opportunities have already 
been demonstrated for TTP. In a shigatoxin-induced TTP 
mouse model, ADAMTS13 gene transfer showed promising 
results for the treatment of congenital TTP.14 For acquired 
TTP, this approach seems prohibited because of the presence 
of autoantibodies against ADAMTS13, unless an eradica-
tion of antibodies can be achieved on constant expression of 
the transgene. Recently, however, transgenic ADAMTS13 
expressed in platelets was demonstrated to prevent both con-
genital and acquired TTP.15 Although a truly elegant approach, 
packing ADAMTS13 into platelets is not directly translatable 
toward patients because this technique is challenging if not 
impossible at the moment. Plasminogen activation has been 
suggested as a possible bypass for ADAMTS13 deficiency 
because plasmin cleavage of VWF reduced the formation 
of VWF-rich microthrombi in Adamts13−/− mice in which 
TTP-like symptoms had been induced with rVWF.16 A recent 
case report described the successful treatment of an acquired 
TTP patient who was unresponsive to plasma exchange with 
N-acetylcysteine.17 This compound, which is clinically used 
for chronic obstructive lung disease, reduces the size of VWF 
multimers by selective breakage of intermolecular disulfide 
bonds.18 Furthermore, inhibition of the VWF–platelet gly-
coprotein Ib interaction using inhibitory anti-VWF antibod-
ies was successful in preventing and treating acquired TTP 
in baboons.19,20 These treatment strategies hold great promise 
in decreasing the number and frequency of plasma exchange 
cycles required to achieve remission. They will, however, 
probably not be able to replace such therapy because they 
neither replenish ADAMTS13 activity nor remove circulating 
antibodies in these patients. By contrast, therapy with rAD-
AMTS13 may overcome these limitations and obviate the 
risky procedure of plasma exchange. Administration of rAD-
AMTS13 has already proved successful in treating congeni-
tal TTP-like symptoms in Adamts13−/− mice triggered with 
rVWF.11
In the present study, we established a small animal model 
for acquired TTP to test whether the recombinant protease is 
proficient in treating TTP-like symptoms also in the presence 
of circulating inhibitory antibodies. Such a setup reflects the 
situation in acquired TTP patients, where circulating anti-
ADAMTS13 antibodies would require high doses of rAD-
AMTS13 to override the inhibitor before a surplus of active 
ADAMTS13 could cleave accumulated ultralarge VWF mul-
timers, thereby preventing thrombotic complications typical 
for TTP. To trigger TTP-like symptoms in our rat model, 2 
pharmacological interventions were needed. Polyclonal 
anti-ADAMTS13 antibodies served to inhibit endogenous 
rat ADAMTS13 and establish a defined level of circulating 
antibodies and a high concentration of rVWF to cause spon-
taneous platelet aggregation and thus thrombocytopenia, 
hemolytic anemia, and VWF-rich thrombi in the kidney and 
brain. Administration of rVWF alone was inadequate to cause 
TTP-like symptoms, probably because it was sufficiently pro-
cessed by endogenous ADAMTS13. Likewise, ADAMTS13 
deficiency induced by the anti-ADAMTS13 antibody was 
not associated with any clinical symptoms, comparable to the 
situation in ADAMTS13-deficient mice.11
In the absence of inhibitory antibodies, the dose required 
to establish an ADAMTS13 activity in rat plasma of 1 U/mL 
can be estimated to be ≈50 U/kg, taking into account rAD-
AMTS13’s in vivo recovery of 60% in rats21 and that a rat 
contains 31 mL plasma per kg body weight.22 Eight-, 16-, 
Figure 5. Recombinant ADAMTS13 (rADAMTS13) treatment 
averts von Willebrand factor (VWF)-rich microthrombi. After 24 h, 
animals were euthanized and tissues were removed for histologi-
cal analysis. Sections were stained for VWF (brown staining) or 
fibrin MSB staining (fibrin bright, red; connective tissue, blue). 
A, Consecutive brain sections stained for VWF (left) and MSB 
fibrin (right) from 0 U/kg group. Scale bars indicate 20 μm. B, 
Representative pictures for VWF staining on brain sections from 
400, 800, and 1600 U/kg groups. Scale bars indicate 20 μm. C, 
Kidney sections stained for VWF. Representative pictures for 0 
and 400 to 1600 U/kg groups are shown. Scale bars indicate 50 
μm. ADAMTS13 indicates a disintegrin and metalloproteinase 
with a thrombospondin type 1 motif, member 13.
 at KU Leuven University Library on September 10, 2015http://atvb.ahajournals.org/Downloaded from 
6  Arterioscler Thromb Vasc Biol  November 2015
and 32-times higher doses of rADAMTS13 were used to 
treat acute TTP-like symptoms (400, 800, and 1600 U/kg); 
these doses were based on a pharmacokinetic study showing 
that 400 U/kg is just sufficient to neutralize an inhibitor titer 
of ≈10 BU/mL (manuscript under revision). Although these 
high doses could have been expected to cause side effects, no 
adverse events, such as an increased bleeding tendency, were 
observed even with 1600 U/kg rADAMTS13. This observa-
tion is concordant with a mouse study where a dose of 3460 U/
kg rADAMTS13 did not induce any adverse events.23
According to the measured ADAMTS13 activity lev-
els in rat plasma, 800 U/kg rADAMTS13 best hit the target 
of 1 U/mL. This dose was efficacious in averting acquired 
TTP because it prevented development of all symptoms of 
the disease observed in untreated animals. Efficacy was also 
demonstrated for the lowest dose tested (400 U/kg), even 
though ADAMTS13 activity only reached endogenous rat 
ADAMTS13 baseline levels (≈0.6 U/mL) and no relevant 
HMW multimer cleavage of rVWF was noted. These observa-
tions clearly suggest that lower than physiological concentra-
tions of ADAMTS13 might suffice to ameliorate the condition 
of patients with acute TTP.
When rADAMTS13 would be administered to patients, 
potential long-term consequences of immune complexes 
formed between rADAMTS13 and the patient anti-
ADAMTS13 autoantibodies need to be also considered. 
Circulating immune complexes between plasma ADAMTS13 
and anti-ADAMTS13 autoantibodies have been demonstrated 
in acquired TTP patients during the acute and the remission 
phase.24 These complexes are suspected to also deposit in 
tissues where they could contribute to the pathogenesis of 
acquired TTP, as demonstrated for other autoimmune dis-
eases, such as systemic lupus erythematosus and rheumatoid 
arthritis. Future studies should therefore address whether 
ADAMTS13-specific immune complexes provoke an immune 
response (eg, complement and leukocyte activation) and asso-
ciate with the disease’s pathogenicity.
In our rat model, we administered rADAMTS13 15 min-
utes after the rVWF trigger, a time point where rats were 
suspected to already show TTP-like symptoms. Indeed, we 
previously demonstrated that thrombocytopenia developed 
within minutes after rVWF injection and concomitant with 
the occurrence of VWF-rich microthrombi.11 Hence, our 
model allowed studying treatment in the early stage of TTP. 
The rat model did not allow rADAMTS13 treatment after a 
substantially longer time window after TTP onset because a 
recovery of TTP symptoms already began after 24 h, as dem-
onstrated by a slight increase in platelet counts and decreased 
LDH activity levels, and because of the reversible nature 
of the effects triggered by the combination of inhibitor and 
rVWF. To study the effect of rADAMTS13 treatment during 
deep thrombocytopenia, the baboon model of acquired TTP 
seems to be better suited because repeated injections of an 
inhibitory monoclonal anti-ADAMTS13 antibody induced 
TTP symptoms without the need for any trigger that lasted 
≤11 days.19,25 Another possible limitation of this study is that 
our rat model does not reflect the continuous antibody pro-
duction as in acquired TTP patients. However, as with plasma 
exchange, treatment with rADAMTS13 will probably also 
need supplemental administration of immunosuppressive 
drugs, such as rituximab, to decrease the continuous produc-
tion of new autoantibodies, thereby preventing them from 
overruling rADAMTS13 therapy.
Acquired TTP patients have a heterogeneous antibody 
profile,26–28 and inhibitory titers may differ not only from 
patient to patient but also from day to day for a single patient.12 
Potential treatment with rADAMTS13 would therefore ben-
efit from a dosing strategy that is tailored to the actual inhibi-
tor titer of these patients. This parameter proved crucial for 
primary dose calculation in vitro12 and was also predictive for 
calculating the amounts of rADAMTS13 required to override 
inhibitors in rats (manuscript under revision). In the clinical 
setting, this strategy would require measuring the inhibitory 
titer before administering rADAMTS13, which, although 
conceptually attractive, may be challenging considering the 
patients’ critical state. Nonetheless, such a strategy would 
allow more informed medical decisions, a higher probability 
of the desired outcome, a reduction in adverse reactions, and 
reduced healthcare costs because of targeted therapy.
A phase I clinical study has recently been initiated to 
assess rADAMTS13 in the treatment and prophylaxis of con-
genital TTP (ClinicalTrials.gov: NCT02216084). Our study 
provides evidence that rADAMTS13 may also be effective in 
treating acquired TTP because it was able to overcome cir-
culating inhibitors and reconstitute ADAMTS13 activity in 
a rat model mimicking acute acquired TTP. Therefore, rAD-
AMTS13 holds promise for the treatment of this severe and 
life-threatening disease in humans.
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The life-threatening disease thrombotic thrombocytopenic purpura is associated with a deficiency in von Willebrand factor–cleaving protease 
ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). For the vast majority of patients, this is 
caused by an acquired formation of autoantibodies inhibiting the activity of ADAMTS13. Treatment of acquired thrombotic thrombocytopenic 
purpura patients currently consists of plasma exchange using fresh frozen plasma, but still 10% to 20% of the patients die during an acute 
episode. Therefore, new treatment strategies are highly warranted. In the present article, we developed a rat model mimicking acquired 
thrombotic thrombocytopenic purpura. With this model, we demonstrated that recombinant ADAMTS13 has the ability to override inhibitory 
antibodies, resulting in prevention of severe thrombotic thrombocytopenic purpura symptoms and restoration of ADAMTS13 activity. Recom-
binant ADAMTS13 thus holds promising value for the treatment of this severe and life-threatening disease in humans.
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Materials and Methods 
 
Anti-ADAMTS13 IgG, human recombinant VWF and rADAMTS13 
Preparation of anti-ADAMTS13 IgG, human recombinant (r)VWF and rADAMTS13 has been 
previously described1-3.  
Wild-type ADAMTS13 was produced in stably transfected Chinese hamster ovary (CHO) 
cells under serum- and protein-free conditions and rADAMTS13 was purified from large-
scale culture harvests by a conventional multistep chromatography procedure. The purified 
rADAMTS13 was formulated in a physiological protein-free buffer and consisted of 0.865 
mg/mL ADAMTS13 antigen and 1426 U/mL ADAMTS13 activity.  
Von Willebrand factor was produced in CHO cells in co-expression with Factor VIII and 
purified from the flow-through of the FVIII capture step including a furin-mediated maturation 
process to yield fully-processed rVWF. Purified rVWF was formulated in a protein-free buffer 
and consisted of 166 U/mL VWF antigen and 205 U/mL VWF activity.  
A polyclonal anti-ADAMTS13 antibody preparation was generated in goats using purified full-
length human rADAMTS13 as antigen. Goat IgG was purified from citrated plasma using 
Protein G sepharose 4 FF (GE Healthcare Life Science) and dissolved in 94 mM Glycin, 60 
mM Tris, pH 5.0. The purified preparation had an inhibitory activity of about 735 BU/mL 
against human ADAMTS13.  
VWF activity was determined using immunoturbidimetric VWF activity (VWF:Ac) assay 
(INNOVANCE® VWF Ac.; BCS system; Siemens, Marburg, Germany). ADAMTS13 activity 
was determined with a fluorescence resonance energy transfer (FRETS)-based assay 
essentially as described4, using the synthetic fluorogenic FRETS-VWF73 minimal peptide as 
substrate (Peptide Institute, Inc., Japan). For reference, pooled normal human plasma (NHP; 
George King Biomedical Inc., Overland Park, USA) was assigned an ADAMTS13 activity 
concentration of 1 U/mL. 
 
Rat model of acquired TTP 
Male Sprague-Dawley rats (9-12 weeks old) were used. For intravenous injection, a 24G 
butterfly needle was inserted into the lateral tail vein of anesthetized animals (isoflurane). 
Goat-anti-ADAMTS13 IgG antibodies (250 µL) were injected at a dose of 650 U/kg body 
weight. Fifteen minutes later, 2000 VWF:RCoU/kg rVWF (3.5 mL) was injected5. Another 15 
min later, rats were treated with 400, 800, or 1600 U/kg rADAMTS13 (400 µL). The butterfly 
needles were removed and the rats allowed to recover from anesthesia. Animal studies were 
approved by the Institutional Animal Care and Use Committee of KU Leuven (Belgium). 
 
Blood collection 
Blood collection was performed at baseline (7 days before the start of the experiment) and 3, 
6 and 24 h after injections. Blood was collected on citrate (7:1 vol/vol of blood:3.8% sodium 
citrate) or EDTA (15:1 vol/vol of blood:0.5 M EDTA) via retro-orbital venipuncture. Total blood 
cell counts were obtained from blood collected on EDTA using the Hemavet 950 (Drew 
Scientific, Dallas, USA). A blood smear was made from citrated whole blood and stained with 
May-Grünwald-Giemsa. Four pictures were made per rat per time point, and the percentage 
of schistocytes (red blood cell fragments) over the total number of red blood cells was 
quantified. Plasma was obtained from blood collected on sodium citrate or EDTA by 
centrifugation at 2500xg for 6 min and stored at -80°C.  
 
Determination of ADAMTS13 activity and LDH levels 
ADAMTS13 activity in rat plasma was evaluated using a fluorogenic VWF substrate (FRETS-
VWF73, Peptide International, Louisville, USA) essentially as described for murine plasma6. 
Citrated plasma samples (undiluted or diluted in heat inactivated normal rat plasma) were 
added to Hepes buffered saline (pH 7.4) with 1 mg/ml BSA, followed by addition of the 
FRETS-VWF73 substrate. FRETS-VWF73 was excited at 355 nm and emission measured at 
460 nm every 3 min for 3 h. Fluorescence intensities were depicted as a function of time and 
! 3!
the slope of the resulting curve was calculated and compared with a standard curve derived 
from slopes of serial dilutions of normal rat plasma set at 100% ADAMTS13 activity. 
ADAMTS13 activity in the presence of 5 mM EDTA was used as a negative control. 
Lactate dehydrogenase (LDH) activity was measured in EDTA plasma using an LDH activity 
colorimetric assay kit (Biovision, Milpitas, USA) according to the manufacturer’s instructions.  
 
Determination of rVWF antigen levels 
Human VWF antigen present in the plasma samples of rats injected with rVWF was 
quantified by ELISA. An in-house developed monoclonal antibody against human VWF (6D1) 
was used to specifically capture rVWF from rat plasma and a polyclonal rabbit anti-human 
VWF was conjugated with horse radish peroxidase (HRP; Dako, Heverlee, Belgium) to 
detect bound VWF. A normal human plasma (NHP) pool from 20 individuals was used to set 
up a calibration curve and undiluted NHP was assigned a VWF antigen concentration of 
100%. 
 
Determination of circulating immune-complexes 
Circulating immune-complexes of goat anti-ADAMTS13 antibodies bound to ADAMTS13 
were measured by ELISA, using an in-house rabbit polyclonal ADAMTS13-specific capture 
antibody (K1-4) and a biotinylated polyclonal rabbit anti-goat IgG as detection antibody 
(Vector Laboratories, Inc., Burlingame, USA) in combination with horseradish peroxidase-
conjugated avidin (Invitrogen Life Technologies, Gent, Belgium) and TMB as substrate 
(Thermo Scientific, Inc., Rockford, USA). The final immune-complex titer was determined as 
the highest dilution of the test sample with an OD above negative control plasma, prepared 
from rat blood taken 3 h after a single intravenous administration of normal goat IgG and 
rADAMTS13.  
 
VWF multimer analysis 
VWF multimer analysis was performed as described7,8. Briefly, VWF was separated on 
sodium dodecyl sulphate (SDS) 1.5% iso electric focusing (IEF) agarose gels. The gels were 
fixed on Gelbond (Cambrex Bio Science Rockland Inc., Rockland, USA) and VWF was 
detected using anti-human VWF-Ig labeled with alkaline phosphatase and a substrate kit 
(BioRad, Hercules, USA). Densitometric analysis was performed using ImageJ software 
(version 1.47, National Institute of Health, Bethesda, USA). For each lane, the complete 
multimer was selected and the density was graphed. The lowest 5 (1-5 mer), the 
intermediate (6-10 mer), and high molecular weight (HMW; >10 mer) multimers were 
selected and the density of the HMW multimers relative to the complete multimer was 
calculated as a percentage.  
 
Histology 
After 24 h, rats were sacrificed by cervical dislocation under isoflurane anesthesia. Following 
exsanguination, heart, kidney, liver, brain and lung tissues were collected and fixed in 4% 
paraformaldehyde. Tissues were embedded in paraffin and 5 µm thick sections were cut. 
Slides were stained with Haematoxylin & Eosin (Sigma-Aldrich) for general histologic 
analysis. Martinus, Scarlet and Blue (MSB) staining was performed to visualize fibrin (red) 
and collagen (blue). Sections were placed into Bouin’s 2000 fixative (American MasterTech, 
Lodi, USA) at 56°C for 1 h, followed by a 0.5% naphthol yellow S solution (Santa Cruz, 
Heidelberg, Germany), a 1% crystal ponceau 6R solution (Santa Cruz), a 1% 
phosphotungstic acid solution (Sigma-Aldrich), and a 0.5% methyl blue solution (Sigma-
Aldrich). VWF was stained using a polyclonal rabbit anti-human VWF antibody (Dako), 
followed by biotinylated swine anti-rabbit F(Ab)2 (Dako) and the Vectastain ABC kit (Vector 
Laboratories, Burlingame, USA). VWF staining was visualized using DAB (Dako) and 
counterstained using Haematoxylin to visualize nuclei.  
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Statistics 
All data are presented as mean ± standard deviation. Statistical comparisons between two 
groups of samples were performed by Mann-Whitney U testing using GraphPad Prism 5 
(GraphPad Software, Inc., La Jolla, USA). A p-value of less than 0.05 was considered 
significant and is indicated with an asterisk (*). A p-value < 0.01 is indicated with two 
asterisks (**). !
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